Literature DB >> 24947955

Interventional therapies for malignant pleural effusions: the present and the future.

Rajesh Thomas1, Roslyn Francis, Helen E Davies, Y C Gary Lee.   

Abstract

The approach to management of malignant pleural effusions (MPE) has changed over the past few decades. The key goals of MPE management are to relieve patient symptoms using the least invasive means and in the most cost-effective manner. There is now a realization that patient-reported outcome measures should be the primary goal of MPE treatment, and this now is the focus in most clinical trials. Efforts to minimize patient morbidity are complemented by development of less invasive treatments that have mostly replaced the more aggressive surgical approaches of the past. Therapeutic thoracentesis is simple, effective and generally safe, although its benefits may only be temporary. Pleurodesis is the conventional and for a long time the only definitive therapy available. However, the efficacy and safety of talc pleurodesis has been challenged. Indwelling pleural catheter (IPC) drainage is increasingly accepted worldwide and represents a new concept to improve symptoms without necessarily generating pleural symphysis. Recent studies support the effectiveness of IPC treatment and provide reassurance regarding its safety. An unprecedented number of clinical trials are now underway to improve various aspects of MPE care. However, choosing an optimal intervention for MPE in an individual patient remains a challenge due to our limited understanding of the underlying pathophysiology of breathlessness in MPE and a lack of predictors of survival and pleurodesis outcome. This review provides an overview of common pleural interventional procedures used for MPE management, controversies and limitations of current practice, and areas of research most needed to improve practice in future.
© 2014 Asian Pacific Society of Respirology.

Entities:  

Keywords:  indwelling pleural catheter; malignant; mesothelioma; pleural effusion; pleurodesis

Mesh:

Year:  2014        PMID: 24947955     DOI: 10.1111/resp.12328

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  14 in total

Review 1.  Review of malignant pleural mesothelioma survival after talc pleurodesis or surgery.

Authors:  Emanuela Taioli; Maaike van Gerwen; Meredith Mihalopoulos; Gil Moskowitz; Bian Liu; Raja Flores
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

Review 2.  Current best practice in the evaluation and management of malignant pleural effusions.

Authors:  Steven Walker; Anna C Bibby; Nick A Maskell
Journal:  Ther Adv Respir Dis       Date:  2016-10-24       Impact factor: 4.031

3.  Feasibility of objectively measured physical activity and sedentary behavior in patients with malignant pleural effusion.

Authors:  Emily Jeffery; Yc Gary Lee; Joanne McVeigh; Leon Straker; Troy Wooding; Robert U Newton; Carolyn Peddle-McIntyre
Journal:  Support Care Cancer       Date:  2017-04-28       Impact factor: 3.603

4.  Conventional versus pigtail chest tube-are they similar for treatment of malignant pleural effusions?

Authors:  Maria Aurora Mendes; Nuno China Pereira; Carla Ribeiro; Manuela Vanzeller; Teresa Shiang; Rita Gaio; Sérgio Campainha
Journal:  Support Care Cancer       Date:  2018-03-30       Impact factor: 3.603

5.  Simple intrapleural hyperthermia at thoracoscopic exploration to treat malignant pleural effusion.

Authors:  Youngkyu Moon; Kyung Soo Kim; Jae Kil Park
Journal:  J Cardiothorac Surg       Date:  2015-10-28       Impact factor: 1.637

6.  Protocol of the Australasian Malignant Pleural Effusion (AMPLE) trial: a multicentre randomised study comparing indwelling pleural catheter versus talc pleurodesis.

Authors:  Edward T H Fysh; Rajesh Thomas; Catherine A Read; Ben C H Kwan; Ben C H Lam; Elaine Yap; Fiona C Horwood; Pyng Lee; Francesco Piccolo; Ranjan Shrestha; Luke A Garske; David C L Lam; Andrew Rosenstengel; Michael Bint; Kevin Murray; Nicola A Smith; Y C Gary Lee
Journal:  BMJ Open       Date:  2014-11-06       Impact factor: 2.692

7.  Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis.

Authors:  Rong Biaoxue; Cai Xiguang; Liu Hua; Gao Wenlong; Yang Shuanying
Journal:  BMC Cancer       Date:  2016-11-14       Impact factor: 4.430

8.  Outcomes of bevacizumab combined with chemotherapy in lung adenocarcinoma-induced malignant pleural effusion.

Authors:  Hong Tao; Qiyi Meng; Mingzhi Li; Liang Shi; Junfang Tang; Zhe Liu
Journal:  Thorac Cancer       Date:  2018-01-03       Impact factor: 3.500

Review 9.  Diagnostic approach to pleural diseases: new tricks for an old trade.

Authors:  Fabien Maldonado; Robert J Lentz; Richard W Light
Journal:  F1000Res       Date:  2017-07-17

10.  Protocol of the Australasian Malignant Pleural Effusion-2 (AMPLE-2) trial: a multicentre randomised study of aggressive versus symptom-guided drainage via indwelling pleural catheters.

Authors:  Maree Azzopardi; Rajesh Thomas; Sanjeevan Muruganandan; David C L Lam; Luke A Garske; Benjamin C H Kwan; Muhammad Redzwan S Rashid Ali; Phan T Nguyen; Elaine Yap; Fiona C Horwood; Alexander J Ritchie; Michael Bint; Claire L Tobin; Ranjan Shrestha; Francesco Piccolo; Christian C De Chaneet; Jenette Creaney; Robert U Newton; Delia Hendrie; Kevin Murray; Catherine A Read; David Feller-Kopman; Nick A Maskell; Y C Gary Lee
Journal:  BMJ Open       Date:  2016-07-05       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.